Biopharma outfits have investigated the use of popular social media sites for spreading a variety of messages and gathering plenty of intelligence.
PatientsLikeMe has found more interest in its online tool for promoting clinical trials to members of its social network. The CRO outfit inVentiv Health and PatientsLikeMe have formed a partnership that could expand the use of services from both companies.
CRA Holdings, the parent company of Clinical Research Advantage, has agreed to buy Radiant Research, expanding its number of trial sites and study capabilities.
We've rounded up 10 ways huge stockpiles of data and large-scale data analysis are changing the biotech game.
At DIA in Philadelphia this week, high-level representatives from CROs sat down for a roundtable discussion with Pharmalot blogger Ed Silverman to discuss the future of CROs and what needs to be done in partnering, innovation and efficacy.
Virtual clinical trials are a hot topic this week at DIA 2012. And a panel today tackled the topic with an emphasis on how mobile technology fits into the range of tools for recruiting patients into clinical studies.
Drugmakers hunt far and wide for patients to take part in their clinical trials, making study recruitment one of the trickiest and time-consuming aspects of product development. Now the software giant Oracle ($ORCL) has set up cloud-based applications that aim to ease the burden of rounding up qualified subjects for clinical studies.
When it comes to Asian countries that are emerging as future leaders in outsourcing, the two countries are being seen as the next up-and-coming spots, according to a new study by GBI Research.
Social media has already proven to be a useful tool to get out the word to potential participants about new clinical trials, but a soup-to-nuts approach to online recruitment and enrollment in a Pfizer study has failed.
A survey of conducted by market research firm Industry Standard Research shows that nearly 90% of surveyed drugmakers would prefer reaching patient recruitment goals at least 10% faster over cutting Phase II or Phase III trial costs 20%.